EndoPore: Tumour targeted non-viral delivery for RNA therapeutics

EndoPore：用于 RNA 治疗的肿瘤靶向非病毒递送

• 批准号: 10061038
• 金额: $ 57.98万
• 依托单位: VITARKA THERAPEUTICS LTD
• 依托单位国家: 英国
• 项目类别: Investment Accelerator
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10061038
• 关键词: EndoPore; Tumour; targeted; non; viral

A new wave of RNA-therapeutics has the potential to transform outcomes for patients with cancers which do not respond to existing small molecule or antibody treatments. RNA-therapeutics have come to the forefront on the back of Covid vaccine success, and many Biotechs are now developing these for currently non-responding patient groups. This £6Bn potential market of new RNA-therapeutics needs a safe drug-delivery technology: to protect the therapeutics from degradation within the body, to target them to the tumour, and to release them inside the cells.Vitarka is a UK life sciences technology SME which is developing a novel intracellular delivery technology, Endo-Pore. Endo-Pore is a drug delivery technology which will carry RNA-therapeutics through the body and then release them within tumour cells - opening up many currently validated but undruggable targets for new anti-cancer treatments.Through this grant, we will substantially de-risk the development path by establishing robust _in vivo_ efficacy of our technology in delivering a clinically relevant therapeutic drug molecule into tumours. We will start validating clinically relevant formulations and define the roadmap for regulatory interaction. This will position the programme for larger scale private investment, and for partnership with biotechs for clinical trials, thereby enabling rapid technological and commercial impact for Vitarka and UK.

新一波的RNA疗法有可能改变对现有小分子或抗体治疗无反应的癌症患者的结果。在新型冠状病毒疫苗成功的背景下，RNA疗法已经走到了最前沿，许多生物技术公司现在正在为目前无反应的患者群体开发这些疗法。这个价值60亿英镑的新型RNA治疗剂的潜在市场需要一种安全的药物递送技术：保护治疗剂在体内不被降解，将其靶向肿瘤，并将其释放到细胞内。Vitarka是一家英国生命科学技术中小企业，正在开发一种新型细胞内递送技术Endo-Pore。Endo-Pore是一种药物输送技术，它将携带RNA治疗剂通过身体，然后将它们释放到肿瘤细胞中-为新的抗癌治疗开辟了许多目前已验证但不可药物化的靶点。通过这笔赠款，我们将通过建立我们的技术在将临床相关的治疗药物分子输送到肿瘤中的强大体内功效，大大降低开发路径的风险。我们将开始验证临床相关制剂，并确定监管互动的路线图。这将使该项目能够获得更大规模的私人投资，并与生物技术公司合作进行临床试验，从而为Vitarka和英国带来快速的技术和商业影响。